Strategic Collaboration DSL partners with Immundiagnostik for DDW presence to showcase fecal gluten peptide testing, signaling a collaborative sales angle to offer integrated diagnostic solutions and expand market reach in gluten-related testing.

Strong Clinical Expertise With a team that has validated over 500 assays and leaders boasting extensive clinical and academic experience, there is an opportunity to position DSL as a trusted partner for high-assurance, specialized diagnostics and for contract research services.

Diversified Test Portfolio DSL has developed multiple COVID-19 related tests and is active in innovative fecal peptide testing for gluten exposure, suggesting potential cross-sell of additional assays and expansion into gastroenterology and infectious disease diagnostics.

Mid‑size Enterprise Positioned in the 51-200 employee range with substantial revenue, DSL is scalable for enterprise-grade collaborations, white-labeling opportunities, and regional or national laboratory network partnerships.

Market Visibility Active participation in major conferences like DDW and a clear focus on timely, cost-effective diagnostic solutions indicate opportunities to engage DSL in channel partnerships, distributor arrangements, or joint marketing initiatives to accelerate adoption.